Donovan Quill, President and CEO, Optime Care, interview featured on April 20, 2021: HealthTech HotSpot

There are 30 million Americans living with a range of 7,000 rare or orphan diseases requiring a high level of therapy adherence support. These individuals have higher medical needs, often missing work, retiring early and relying on caregiver assistance.

This leads to considerable direct and indirect economic burden for patients with orphan and rare diseases, the unpaid family caregivers and the health system – in addition to the medical costs of managing the disease and other costs.

This article highlights Optime Care’s patient-first business model and their effective innovative solution that includes high-tech connectivity. Optime Care’s specialty Rx pharmacist expertise is critical for securing insurance coverage and minimizes the daily impact of rare and orphan diseases while relieving the economic burden of managing a patient’s condition in a way that improves outcomes.